
    
      This is an open label, randomized, active drug comparative, Parallel group, Multi-center,
      phase IV study. Patients receive candemore tablet or atacand tablet. Initial dose is 4mg/day
      or 8mg/day. Every 2 weeks, patients take double dose if patients blood pressure is measured
      SBP â‰¥ 100mmHg and DBP > 60mmHg. Maximum dose is 16mg/day.
    
  